Evidence map›Paper›PMID 41882531›Full record

ArticleBMC microbiology2026

Gut microbiome disruption in Tanzanian pulmonary tuberculosis patients: links to treatment, nutritional status, and host immunity.

Vesla I Kullaya, Sylvia Rofael, Scott K Heysell, Tania A Thomas, Nehemiah Ongeso, Kimita Gathii, Bibie Said, Stellah Mpagama, Blandina T Mmbaga, Timothy D McHugh

Abstract read
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vesla I KullayaKilimanjaro Clinical Research Institute (KCRI), Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania.
Sylvia RofaelDivision of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, UK.
Scott K HeysellDivision of Infectious Diseases & International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Tania A ThomasDivision of Infectious Diseases & International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Nehemiah OngesoKenya Medical Research Institute/Walter Reed Army Institute of Research-Africa/Basic Science Laboratory, Kisumu, Kenya.
Kimita GathiiKenya Medical Research Institute/Walter Reed Army Institute of Research-Africa/Basic Science Laboratory, Kisumu, Kenya.
Bibie SaidKibong'oto Infectious Diseases Hospital, Mae, Sanya Juu, Siha, Tanzania.
Stellah MpagamaKibong'oto Infectious Diseases Hospital, Mae, Sanya Juu, Siha, Tanzania.
Blandina T MmbagaKilimanjaro Clinical Research Institute (KCRI), Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania.
Timothy D McHughDivision of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, UK. t.mchugh@ucl.ac.uk.

Funding

Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and AdultsR01AI137080 · NIAID · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, Leonid Kagan · 2018 to 2026
$6.3M
Developing research leaders at the intersection of malnutrition and tuberculosis in TanzaniaD43TW012247 · FIC · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, STELLAH GEORGE MPAGAMA · 2022 to 2026
$1.4M
Africa Research Excellence Fund (AREF) AREF-325-KULL-F-C0956FIC NIH HHS D43 TW012247NIAID NIH HHS R01 AI137080
6 · The paper itself

Abstract

Tuberculosis (TB) and its treatment disrupt the gut microbiome, potentially impacting immune regulation and treatment outcomes. However, host-microbial interactions during TB disease are not well characterized. This cross-sectional study investigated the gut microbiome of pulmonary tuberculosis patients—both newly diagnosed and those treated for two months—compared to healthy controls in Tanzania. TB treatment was associated with reduced microbial diversity, distinct clustering, and depletion of Euryarchaeota and Cyanobacteria. Treated patients also showed increased Fusobacteria and Tenericutes compared to controls. In contrast, newly diagnosed patients had gut microbiomes similar to controls. Malnutrition and elevated inflammatory cytokines were more common in newly diagnosed patients. Within this group, gut microbial composition varied by nutritional status, cytokine levels, and exposure to pre-diagnosis non-antituberculous antibiotics. Our findings demonstrate that TB treatment significantly alters the gut microbiome and suggest complex interactions between gut microbial populations, host inflammation, nutrition, and treatment history. This study also underscores the need for more microbiome research in Sub-Saharan Africa to better understand immune-microbiome dynamics in TB.

Indexed as

Gastrointestinal MicrobiomeNutritional StatusTuberculosis, PulmonaryAdultAntitubercular AgentsBacteriaCross-Sectional StudiesCytokinesDysbiosisFemaleHumansMaleMiddle AgedTanzaniaAntitubercular AgentsCytokinesAnti-tuberculosis treatmentGut microbiomeInflammatory cytokinesMalnutritionMicrobiome dysbiosisTuberculosis

Identifiers

PMID41882531
PMCPMC13141388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.